Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Comment by CleverInvestor2on May 18, 2020 12:00pm
157 Views
Post# 31042290

RE:RE:RE:Quarterly Report

RE:RE:RE:Quarterly Report
birch1 wrote: apparently they dropped the ATM, so something is up.


Do you have a link for this? That'd be great news. I saw their recent quarter report and they confirmed my intitial thoughts of having enough cash to last them into 2022... and by than we'll know if this drug is the real deal or not... and by that point, we can raise at a much higher price, which means less dilution... or possible buyout...

It wasn't too long ago our main competitors got bought out for 5B.... we're not even valued at 1B right now... so lots of upside.
<< Previous
Bullboard Posts
Next >>